Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg.
This medicine is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually.
The initial dose of this medicine should be based on the patient’s current treatment regimen.
1. Patients not currently receiving metformin:
For patients with no prior experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily.
Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use 2. Patients who must not receive this medicine).
2. Patients receiving metformin:
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose.
- Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin.
3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use 5. General Precautions).
No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed.
Patients with renal impairment
This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment.
Treatment should not be initiated with this medicine, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months.
If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.
Patients with hepatic impairment
This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Patients who must not receive this medicine).
Improvement of glycemic control in type 2 diabetes mellitus
Type 2 diabetes
difficulty in blood sugar control
View approved original textHide original text
This medication is used alongside dietary and exercise therapy to assist with blood sugar control in patients with type 2 diabetes. It is used when patients starting drug therapy cannot achieve sufficient blood sugar control with monotherapy, and if blood sugar control is inadequate with either metformin or sitagliptin alone, it can be substituted or used in combination. Additionally, it can be administered together if there is insufficient efficacy with combination therapy of metformin and sulfonylureas or metformin and thiazolidinediones. If there is inadequate effect in the combined therapy of insulin and metformin, this drug may also be added to help improve blood sugar control. It is used in various treatment scenarios to enhance and improve blood sugar control.
How to take
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg.
This medicine is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually.
The initial dose of this medicine should be based on the patient’s current treatment regimen.
1. Patients not currently receiving metformin:
For patients with no prior experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily.
Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use 2. Patients who must not receive this medicine).
2. Patients receiving metformin:
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose.
- Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin.
3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use 5. General Precautions).
No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed.
Patients with renal impairment
This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment.
Treatment should not be initiated with this medicine, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months.
If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.
Patients with hepatic impairment
This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Patients who must not receive this medicine).
Precautions
This medication contains the active ingredients sitagliptin and metformin, and is used for diabetes treatment.
First, this medication may cause rare but serious allergic reactions, so if symptoms such as rash, urticaria, or swelling of the face or neck appear, it is important to stop taking it immediately and consult a doctor.
Second, acute pancreatitis may occur; thus, if sudden abdominal pain, vomiting, or nausea occurs, one should visit a hospital immediately.
Third, lactic acidosis, a serious metabolic disorder, may occur due to the metformin component, so it is contraindicated for individuals with poor kidney function, dehydration, severe infections, or heart issues. If any symptoms are suspected, it is crucial to inform a healthcare professional immediately.
Fourth, patients with moderate to severe impairment of kidney function, severe heart disease, those in acute infection states, and women who are pregnant or breastfeeding should not use this medication.
Fifth, while taking this medication, regular monitoring of kidney function, blood tests, and vitamin B12 levels is necessary, especially for the elderly, as they are more prone to kidney function decline.
Sixth, there is a risk of hypoglycemia, so meals should be regular, and vigorous exercise or alcohol consumption should be avoided, particularly if taken with other hypoglycemic agents where symptoms of hypoglycemia require extra caution.
Seventh, before surgery or radiographic examinations involving contrast agents, this medication should be temporarily withheld and resumed only after normal kidney function is confirmed.
Eighth, there are various drugs that may interact with this medication, so it is essential to inform a doctor or pharmacist of any other medications being taken, especially those affecting kidney function.
Finally, the safety and efficacy of this medication have not been established in children or adolescents under 18 years of age, so its use is not recommended.
Side effects
Anaphylaxis
angioedema
Stevens-Johnson syndrome
acute pancreatitis
lactic acidosis
hypoglycemia
diarrhea
upper respiratory infection
headache
nausea
Show 22 moreCollapse
vomiting
abdominal pain
nasopharyngitis
constipation
severe and disabling arthralgia
vesicular pemphigoid
myalgia
limb pain
back pain
interstitial lung disease
pruritus
thrombocytopenia
dermatitis
anorexia
weight loss
dyspnea
unstable angina
dizziness
acute renal failure
decreased appetite
gastrointestinal disorder
itching
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a well-closed container that allows for air circulation, at room temperature between 1°C and 30°C. This helps maintain its efficacy and prevent degradation.
Appearance and packaging
Appearance
Pink oval film-coated tablet
Package unit
30 tablets/box [(10 tablets/PTP x 3)]
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.